# PromiseBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/promisebio

- Industry: Biotechnology
- Headquarters: Tel Aviv, Israel
- Website: www.promise.bio
- Total disclosed funding: $8.3M
- Latest round: Seed (Apr 1, 2023)
- Investors on record: 3

## About

Based in Tel Aviv, Israel, and founded in 2023, PromiseBio is a biotechnology company that develops a virtual AI platform to identify Post-Translational Modifications in proteins. In December 2024, PromiseBio raised an undisclosed amount in grant funding from new investor Israel Innovation Authority.

PromiseBio focuses on precision medicine for autoimmune diseases, using a cloud-based AI platform to analyze protein changes, specifically post-translational modifications (PTMs) that control protein activity. The company technology helps to understand disease mechanisms and identify biomarkers by using advanced algorithms and explainable AI. PromiseBio's solutions are mainly aimed at the biopharmaceutical industry, particularly companies involved in drug development and clinical trials in North America and Europe. The platform supports treatment selection, early response evaluation, and disease monitoring, with the goal of improving patient outcomes in autoimmune diseases.

The company will use the December 2024 funding to help quicken its platform's development, increase its capacity for research, and scale its state-of-the-art technology.

## Funding rounds

- Seed, Apr 1, 2023, $8.3M — AstraZeneca, Pfizer Venture Investments, AWZ Ventures

## Investors

- AstraZeneca — Seed
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Seed
- AWZ Ventures (https://capitalatlas.ai/funds/awz-ventures) — Seed